Involvement of opioid receptors in phencyclidine-induced enhancement of brain histamine turnover in mice

Publisher Website
Google Scholar
Abstract
When the histamine (HA) turnover in the brain of mice was estimated on the basis of the pargyline-induced accumulation of tele-methylhistamine (t-MH), a predominant metabolite of brain HA, the enhancing effect of phencyclidine (PCP) on the HA turnover was antagonized by a large dose of naloxone. However, a dopamine receptor antagonist haloperidol, which is also a potent σ receptor antagonist, did not inhibit the effect of PCP on the HA turnover. [abetd-Ala2, abetd-Leu5]enkephalin, a prototypic δ opioid agonist, markedly enhanced the HA turnover. The effect of this peptide was demonstrated not only when the HA turnover was determined by the pargyline-induced t-MH accumulation but when it was estimated by the HA depletion induced by α-fluoromethylhistidine, a specific inhibitor of histidine decarboxylase. A σ agonist, SKF-10047, and a κ agonist, ethylketazocine, had no PCP-like enhancing effect on the HA turnover. These results suggest that PCP enhances the brain HA turnover in mice by stimulating, probably indireclty, endogenous opioid systems.